Advertisement
Singapore markets closed
  • Straits Times Index

    3,497.78
    +22.72 (+0.65%)
     
  • Nikkei

    41,190.68
    -1,033.34 (-2.45%)
     
  • Hang Seng

    18,293.38
    +461.05 (+2.59%)
     
  • FTSE 100

    8,252.91
    +29.57 (+0.36%)
     
  • Bitcoin USD

    59,970.66
    +1,566.29 (+2.68%)
     
  • CMC Crypto 200

    1,250.98
    +52.41 (+4.37%)
     
  • S&P 500

    5,615.35
    +30.81 (+0.55%)
     
  • Dow

    40,000.90
    +247.15 (+0.62%)
     
  • Nasdaq

    18,398.45
    +115.04 (+0.63%)
     
  • Gold

    2,416.00
    -5.90 (-0.24%)
     
  • Crude Oil

    82.18
    -0.44 (-0.53%)
     
  • 10-Yr Bond

    4.1890
    -0.0040 (-0.10%)
     
  • FTSE Bursa Malaysia

    1,619.06
    -4.06 (-0.25%)
     
  • Jakarta Composite Index

    7,327.58
    +27.17 (+0.37%)
     
  • PSE Index

    6,648.23
    +38.99 (+0.59%)
     

CRISPR Therapeutics: A Galaxy's Worth of Deep Value

CRISPR Therapeutics: A Galaxy's Worth of Deep Value

CRISPR Therapeutics (NASDAQ: CRSP) has been making headlines lately as a result of its groundbreaking gene-editing collaboration with Vertex Pharmaceuticals (NASDAQ: VRTX). The backstory is that the two companies recently filed for a spate of regulatory approvals for the CRISPR/Cas9 gene-edited product, exa-cel, as a functional cure for two rare blood disorders, sickle cell disease and transfusion-dependent beta thalassemia. What arguably hasn't been appreciated, however, is CRISPR's other clinical assets in immuno-oncology, regenerative medicine, and in vivo therapeutics.